Melanoma Management最新文献

Efficacy and safety of adjuvant systemic therapies in trial non-eligible resected stages III and IV melanoma patients. 辅助全身治疗在不符合条件的III期和IV期黑色素瘤切除患者中的疗效和安全性。

IF 1

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-02-17 DOI: 10.1080/20450885.2025.2461963

Sarah Alsadiq, Adi Kartolo, Elaine McWhirter, Wilma Hopman, Tara Baetz

{"title":"Efficacy and safety of adjuvant systemic therapies in trial non-eligible resected stages III and IV melanoma patients.","authors":"Sarah Alsadiq, Adi Kartolo, Elaine McWhirter, Wilma Hopman, Tara Baetz","doi":"10.1080/20450885.2025.2461963","DOIUrl":"10.1080/20450885.2025.2461963","url":null,"abstract":"Background: Adjuvant immunotherapy and targeted therapy are now the standard of care for patients with resected stage IIIA-IV melanoma. However, little is known regarding its efficacy in real-world patients who were not represented in these landmark trials.Methods: This retrospective study included all patients with resected stage IIIA-IV melanoma who received adjuvant systemic therapy between January 1 2018 and December 31 2020, in two Canadian academic cancer. Primary outcome was the proportion of trial non-eligible patients in the real-world setting. Survival and safety analyses were also conducted.Results: Of the total 113 patient, 99 (88%) were trial non-eligible patients. Most common reasons for trial non-eligible criteria was having no baseline CLND (72%), followed by outside of treatment window >12 weeks (30%), stage IIIA (14%), unknown primary (9%), stage IV (14%), and baseline AD on immunosuppressants (3%). There were no significant RFS (P = 0.731) or OS (P = 0.110) differences in the overall population of trial eligible vs. non-eligible. Safety profiles were similar between the trial eligible vs. non-eligible groups.Conclusion: Our study suggested a high proportion of real-world patients would have been deemed non-eligible for clinical trials. Regardless, adjuvant systemic therapy delivered similar survival and toxicity outcomes in both groups.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2461963"},"PeriodicalIF":1.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Threshold analysis of mortality outcomes in the collaborative ocular melanoma study (COMS). 协同眼黑色素瘤研究（COMS）死亡率结果的阈值分析。

IF 1

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-05-05 DOI: 10.1080/20450885.2025.2494977

Viktor T Gill, Shiva Sabazade, Gustav Stålhammar

{"title":"Threshold analysis of mortality outcomes in the collaborative ocular melanoma study (COMS).","authors":"Viktor T Gill, Shiva Sabazade, Gustav Stålhammar","doi":"10.1080/20450885.2025.2494977","DOIUrl":"https://doi.org/10.1080/20450885.2025.2494977","url":null,"abstract":"Aim: The collaborative ocular melanoma study (COMS) reported similar survival between plaque brachytherapy (a type of interventional radiotherapy) and enucleation for medium-sized choroidal melanomas. We aimed to quantify the mortality differences required to achieve statistical significance and assess the robustness of these thresholds.Methods: We reanalyzed 12-year mortality data from COMS using threshold analysis to determine how many additional or fewer deaths in either treatment arm would shift the lower bound of the 95% confidence interval (CI) for the risk ratio above 1.Results: At 12 years, there were 105 melanoma-related deaths in the brachytherapy arm and 98 in the enucleation arm (risk ratio 1.08, 95% CI 0.82-1.42). Achieving statistical significance would have required 31 additional deaths in the brachytherapy arm or 23 fewer in the enucleation arm; conversely, favoring brachytherapy would have necessitated 34 additional deaths in the enucleation arm or 27 fewer in the brachytherapy arm. These thresholds remained consistent across power levels and sensitivity scenarios.Conclusions: The COMS trial did not reveal a clinically meaningful survival difference. Our findings underscore the substantial mortality shifts required for statistical significance and highlight the challenges in detecting modest treatment effects in uveal melanoma trials.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2494977"},"PeriodicalIF":1.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A bibliometric analysis of sentinel lymph node biopsy in melanoma of the top 90 cited publications. 前90位被引出版物中黑色素瘤前哨淋巴结活检的文献计量学分析。

IF 1

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-04-28 DOI: 10.1080/20450885.2025.2494979

Zhen Yu Wong, Aisha Chaudry, Samuel Teklay, Zhen Ning Wong, Oluwatobi Adegboye, Pojsakorn Danpanichkul, Ryan Faderani, Muholan Kanapathy, Afshin Mosahebi

{"title":"A bibliometric analysis of sentinel lymph node biopsy in melanoma of the top 90 cited publications.","authors":"Zhen Yu Wong, Aisha Chaudry, Samuel Teklay, Zhen Ning Wong, Oluwatobi Adegboye, Pojsakorn Danpanichkul, Ryan Faderani, Muholan Kanapathy, Afshin Mosahebi","doi":"10.1080/20450885.2025.2494979","DOIUrl":"https://doi.org/10.1080/20450885.2025.2494979","url":null,"abstract":"Background: This bibliometric analysis aims to describe research trends and assess the methodological quality of the highest-impact SLNB research in melanoma.Methods: We identified the 90 most cited publications on SLNB in melanoma using Web of Science, covering all available journal years (from 2005 to date). The Oxford Center for Evidence-Based Medicine (OCEBM) Levels of Evidence (LOE) were used to assess the methodological quality of each study.Results: The 90 most cited publications on SLNB in melanoma collectively garnered 10,314 citations. Citation counts per publication ranged from 44 to 1,405 (mean 114.6 ± 185.2), with the highest-cited study authored by Professor Donald Morton et al. The majority of publications was classified as LOE 3 (n = 36). The United States of America (USA) led in publication output with 43 articles. Professors Merrick Ross (USA) and John Thompson (Australia) were the leading authors by publication count. The University of Sydney (Australia), University of Texas System, and Anderson Cancer Center (USA) were the top contributing institutions. Annals of Surgical Oncology published most articles.Conclusions: This bibliometric analysis provides a comprehensive overview and valuable reference for future researchers in the field of SLNB in melanoma.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2494979"},"PeriodicalIF":1.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case report of LVEF derived from gated FDG-PET: potential to streamline cardiotoxic surveillance in melanoma patients. 门控FDG-PET衍生的LVEF病例报告：简化黑色素瘤患者心脏毒性监测的潜力。

IF 1

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-05-28 DOI: 10.1080/20450885.2025.2510194

Marc Østergaard Nielsen, Johan Erik Larsson, Linus Daniel Leonhard Duchstein, Lars Thorbjørn Jensen

{"title":"Case report of LVEF derived from gated FDG-PET: potential to streamline cardiotoxic surveillance in melanoma patients.","authors":"Marc Østergaard Nielsen, Johan Erik Larsson, Linus Daniel Leonhard Duchstein, Lars Thorbjørn Jensen","doi":"10.1080/20450885.2025.2510194","DOIUrl":"https://doi.org/10.1080/20450885.2025.2510194","url":null,"abstract":"Background: Advances in cancer therapy have improved patient outcomes, but cardiotoxicity remains a significant risk. In melanoma patients treated with BRAF and MEK inhibitors, monitoring left ventricular ejection fraction (LVEF) during treatment is recommended to detect cardiac dysfunction. Despite the widespread use of FDG-PET in oncology, its potential for concurrent cardiac assessment remains underexplored.Methods: A 42-year-old male undergoing treatment for disseminated melanoma underwent measurements of LVEF using four modalities: 3D-MUGA, 3D echocardiography, Rb-PET, and gated FDG-PET.Results: LVEF was within the normal range across all modalities: 60% (3D-MUGA), 61% (3D echocardiography), 63% (Rb-PET), and 65% (FDG-PET).Conclusion: This case presents an estimation of LVEF derived from a clinically indicated, FDG-PET scan, performed alongside three conventional modalities on the same day. This approach may be particularly useful in melanoma patients who undergo frequent FDG-PET scans. While the findings are promising, broader validation is needed.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2510194"},"PeriodicalIF":1.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates in clinical trial-explored chemopreventive agents for cutaneous melanoma: mechanisms affecting melanocytes. 皮肤黑色素瘤的临床试验探索化学预防药物的最新进展：影响黑色素细胞的机制。

IF 1

Melanoma Management Pub Date : 2025-05-13 Epub Date: 2025-05-16 DOI: 10.1080/20450885.2025.2505400

Gelare Ghajar-Rahimi, Nabiha Yusuf

{"title":"Updates in clinical trial-explored chemopreventive agents for cutaneous melanoma: mechanisms affecting melanocytes.","authors":"Gelare Ghajar-Rahimi, Nabiha Yusuf","doi":"10.1080/20450885.2025.2505400","DOIUrl":"10.1080/20450885.2025.2505400","url":null,"abstract":"Cutaneous melanoma is a highly aggressive skin cancer with rising incidence, driven by risk factors such as ultraviolet exposure, genetic predisposition, and immunosuppression. While surgical excision remains the primary treatment, interest in chemoprevention strategies is growing. Numerous natural and synthetic agents have shown preclinical promise, but evaluating their effectiveness is challenging due to their systemic effects on multiple cell types. This review provides a focused examination of the melanocyte-specific mechanisms of select agents that have been tested in clinical trials for melanoma chemoprevention. We discuss various molecular and cellular mechanisms driving the anti-melanoma properties of nonsteroidal anti-inflammatory drugs, statins, sulforaphane, vitamin D, and N-acetylcysteine. Despite promising preclinical and early clinical data, challenges remain regarding precise mechanisms, optimal dosing, long-term safety, and patient selection. Future research should focus on refining melanoma prevention strategies through well-designed clinical trials and personalized approaches integrating genetic and molecular risk factors.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2505400"},"PeriodicalIF":1.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A rare and challenging case of amelanotic subungual melanoma from Syria. 来自叙利亚的罕见且具有挑战性的无黑色素瘤趾骨下黑色素瘤病例。

IF 1

Melanoma Management Pub Date : 2024-12-01 Epub Date: 2024-12-29 DOI: 10.1080/20450885.2024.2442874

Muhammad Anas Kudsi, Anas Alsheikh Hamdoun, Osama Haj Osman, Lina Ghabreau, Nour Hakim, Aladdin Etr

引用次数: 0

BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy. braf突变黑色素瘤的管理：单中心回顾性分析患者接受序贯治疗。

IF 1

Melanoma Management Pub Date : 2024-12-01 Epub Date: 2024-11-29 DOI: 10.1080/20450885.2024.2432826

Ilaria Proietti, Elena De Falco, Luca Pacini, Alessandra Spagnoli, Velia Melone, Vincenzo Petrozza, Claudio Di Cristofano, Giorgio Mangino, Giovanna Romeo, Paolo Rosa, Antonella Calogero, Concetta Potenza

{"title":"BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy.","authors":"Ilaria Proietti, Elena De Falco, Luca Pacini, Alessandra Spagnoli, Velia Melone, Vincenzo Petrozza, Claudio Di Cristofano, Giorgio Mangino, Giovanna Romeo, Paolo Rosa, Antonella Calogero, Concetta Potenza","doi":"10.1080/20450885.2024.2432826","DOIUrl":"10.1080/20450885.2024.2432826","url":null,"abstract":"Aims: In treating patients with melanoma, the order in which therapy is administered, choosing between targeted therapy and immune checkpoint inhibition, has garnered growing interest.Patients and methods: We conducted a retrospective, real-world analysis of patients with advanced melanoma undergoing immunotherapy or targeted therapy as first-line at a single center.Results: A total of 88 patients diagnosed with melanoma were identified. At 7 years, in this cohort, 68.4% (95% CI: 55.9%-83.6%) of patients were alive. In all, 47 tumors harbored BRAF mutations; 10 patients who did not receive therapy were excluded from this subgroup. Of the 37 patients with a BRAF mutation, 29 received first-line targeted therapy and 8 received first-line immunotherapy. At 2 years, 28 (76%) patients were alive and 9 (24%) had died. Of the 28 survivors, 22 received first-line targeted therapy and 6 received first-line immunotherapy. In addition, 29 patients were administered a MEK inhibitor in first line. Of these, 66.4% (95% CI: 48.3-91.2) of patients were alive at 7 years.Conclusions: There was no significant difference between survival and first-line immunotherapy or first-line targeted therapy. Additional studies are required to establish whether front-line immunotherapy is linked to more effective long-term disease control compared to first-line targeted therapy.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"11 1","pages":"2432826"},"PeriodicalIF":1.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitors in pediatric patients with melanoma: a systematic literature review. 免疫检查点抑制剂在儿童黑色素瘤患者中的应用：系统文献综述。

IF 1

Melanoma Management Pub Date : 2024-12-01 Epub Date: 2024-08-26 DOI: 10.1080/20450885.2024.2382075

Charmy Vyas, Andriy Moshyk, Gina Fusaro, Stergios Zacharoulis, Mir Sohail Fazeli, Nishu Gaind, Shirin Behyan, Pratik Thakkar

引用次数: 0

Melanoma in a Colombian population: a survival study. 哥伦比亚人群中的黑色素瘤：一项生存研究。

IF 1

Melanoma Management Pub Date : 2024-12-01 Epub Date: 2024-08-05 DOI: 10.1080/20450885.2024.2382079

Mauricio Arias Flórez, Germán Alberto Moreno Gómez, Mateo Aguirre Flórez, Isaac López Bueno, Juanita Moreno Gómez, Mateo Moreno Gómez, Juan José Restrepo Gutiérrez

引用次数: 0

Patterns in progression from early-stage melanoma to late-stage melanoma: implications for survivorship follow-up. 从早期黑色素瘤发展到晚期黑色素瘤的模式：对幸存者随访的影响。

IF 1

Melanoma Management Pub Date : 2024-12-01 Epub Date: 2024-12-02 DOI: 10.1080/20450885.2024.2424708

David J Savage, Benjamin Switzer, Rujul Parikh, Jung Min Song, Carolyn Stanek, Joshua Arbesman, Lucy Boyce Kennedy, Pauline Funchain

引用次数: 0